Eli Lilly (NYSE: LLY)
Eli Lilly Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Eli Lilly Company Info
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
News & Analysis
The Largest Companies by Market Cap in 2024
Apple, Nvidia, and Microsoft are the biggest companies by market cap.
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects.
The Best CRISPR Companies to Invest In
These CRISPR stocks could be big winners for patient investors.
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.
Why Eli Lilly Stock Is Sinking Today
The big pharmaceutical company provided a disappointing Q3 update.
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth.
Is Eli Lilly Stock a Buy?
Eli Lilly has been a huge winner with its GLP-1 drugs.
Valuation
Earnings Transcripts
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2024.
Eli Lilly (LLY) Q2 2024 Earnings Call Transcript
LLY earnings call for the period ending June 30, 2024.
Eli Lilly (LLY) Q1 2024 Earnings Call Transcript
LLY earnings call for the period ending March 31, 2024.
Eli Lilly (LLY) Q4 2023 Earnings Call Transcript
LLY earnings call for the period ending December 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.